lMEDICINAL FORMS
There can be variation in the licensing of different medicines
containing the same drug.
Capsule
▶Alu-Cap(Meda Pharmaceuticals Ltd)
Aluminium hydroxide 475 mgAlu-Cap 475 mg capsules|
120 capsulep£ 13. 71 DT = £ 13. 71
ELECTROLYTES AND MINERALS›CALCIUM
eiiiiF 592Calcium acetate
lINDICATIONS AND DOSE
PHOSEX®TABLETS
Phosphate binding in renal failure and
hyperphosphataemia
▶BY MOUTH
▶Child:Dose to be adjusted according to requirements of
patient, dose to be taken with meals (consult product
literature)lINTERACTIONS→Appendix 1 : calcium salts
lSIDE-EFFECTS
▶UncommonVomiting
lDIRECTIONS FOR ADMINISTRATION
PHOSEX®TABLETSPhosex®tablets are taken with meals.
Tablets can be broken to aid swallowing, but not chewed
(bitter taste).
lPRESCRIBING AND DISPENSING INFORMATIONPhosex®
tablets contain calcium acetate 1 g (equivalent to calcium
250 mg or Ca^2 + 6. 2 mmol).
lPATIENT AND CARER ADVICE
Medicines for Children leaflet: Calcium salts for kidney disease
http://www.medicinesforchildren.org.uk/calcium-salts-kidney-
disease- 0
PHOSEX®TABLETSPatients or carers should be given
advice on how to administerPhosex®tablets.
lMEDICINAL FORMS
There can be variation in the licensing of different medicines
containing the same drug. Forms available from special-order
manufacturers include: tablet
Tablet
CAUTIONARY AND ADVISORY LABELS 25
▶Phosex(Pharmacosmos UK Ltd)
Calcium acetate 1 gramPhosex 1 g tablets| 180 tabletP£ 19. 79
DT = £ 19. 79
PHOSPHATE BINDERS
Sevelamer 19-Mar-2018
lINDICATIONS AND DOSE
RENAGEL®
Hyperphosphataemia in patients on haemodialysis or
peritoneal dialysis
▶BY MOUTH
▶Child 12–17 years:Initially 0. 8 – 1. 6 g 3 times a day, dose
to be given with meals and adjusted according to
serum-phosphate concentration
RENVELA®2.4G ORAL POWDER SACHETS
Hyperphosphataemia in chronic kidney disease
▶BY MOUTH
▶Child 6–17 years (body surface area 0.75–1.1 m^2 ):Initially
2. 4 g daily in 3 divided doses, dose to be taken with
meals and adjusted according to serum-phosphate
concentration every 2 – 4 weeks—consult product
literature▶Child 6–17 years (body surface area 1.2 m^2 and above):
Initially 4. 8 g daily in 3 divided doses, dose to be taken
with meals and adjusted according to serum-phosphate
concentration every^2 –^4 weeks—consult product
literaturelUNLICENSED USE
RENAGEL®Not licensed for use in children under 18 years.
lCONTRA-INDICATIONSBowel obstruction
lCAUTIONSGastro-intestinal disorders
lSIDE-EFFECTS
▶Common or very commonConstipation.diarrhoea.
gastrointestinal discomfort.gastrointestinal disorders.
nausea.vomiting
▶Frequency not knownSkin reactions
lPREGNANCYManufacturer advises use only if potential
benefit outweighs risk.
lBREAST FEEDING
RENVELA®2.4G ORAL POWDER SACHETSUnlikely to be
present in milk (however, manufacturer advises avoid).
RENAGEL®Manufacturer advises use only if potential
benefit outweighs risk.
lDIRECTIONS FOR ADMINISTRATION
RENVELA®2.4G ORAL POWDER SACHETSManufacturer
advises each sachet should be dispersed in 60 mL water, or
mixed with a small amount of cool food ( 100 g), prior to
administration and discarded if unused after 30 minutes.
lPATIENT AND CARER ADVICE
Medicines for Children leaflet: Sevelamer in dialysis
http://www.medicinesforchildren.org.uk/sevelamer-in-dialysis
RENVELA®2.4G ORAL POWDER SACHETSPatients and
carers should be advised on how to administer powder for
oral suspension.
lNATIONAL FUNDING/ACCESS DECISIONS
RENVELA®2.4G ORAL POWDER SACHETS
Scottish Medicines Consortium (SMC) Decisions
TheScottish Medicines Consortiumhas advised (February
2018 ) that sevelamer carbonate (Renvela®) is accepted for
restricted use within NHS Scotland as second-line
management of hyperphosphataemia in paediatric
patients (greater than 6 years of age and a Body Surface
Area greater than 0. 75 m^2 ) with chronic kidney disease
receiving haemodialysis.lMEDICINAL FORMS
There can be variation in the licensing of different medicines
containing the same drug.
Powder
CAUTIONARY AND ADVISORY LABELS 13
▶Renvela(Sanofi)
Sevelamer carbonate 2.4 gramRenvela 2. 4 g oral powder sachets
sugar-free| 60 sachetP£ 167. 04 DT = £ 167. 04
Tablet
CAUTIONARY AND ADVISORY LABELS 25
EXCIPIENTS:May contain Propylene glycol
▶Renagel(Sanofi)
Sevelamer 800 mgRenagel 800 mg tablets| 180 tabletP
£ 167. 04 DT = £ 30. 52BNFC 2018 – 2019 Hyperphosphataemia 599
Blood and nutrition9